## **Core Concept**
Tubocurarine is a non-depolarizing neuromuscular blocking agent that acts by competitively inhibiting the **nicotinic acetylcholine receptors** at the neuromuscular junction. This results in muscle paralysis by preventing acetylcholine from triggering muscle contraction.

## **Why the Correct Answer is Right**
The action of tubocurarine can be reversed by increasing the concentration of acetylcholine in the synaptic cleft. **Neostigmine**, an acetylcholinesterase inhibitor, prevents the breakdown of acetylcholine by inhibiting the enzyme responsible for its degradation. This increases the amount of acetylcholine available to compete with tubocurarine for receptor sites, effectively reversing the neuromuscular blockade.

## **Why Each Wrong Option is Incorrect**
* **Option A:** Sugammadex is a selective relaxant binding agent used to reverse the effects of certain non-depolarizing neuromuscular blockers, but it is not typically used for tubocurarine.
* **Option B:** Atropine is an anticholinergic agent that can be used alongside neostigmine to prevent muscarinic side effects but does not reverse neuromuscular blockade.
* **Option D:** Physostigmine is an acetylcholinesterase inhibitor similar to neostigmine but is not the preferred agent for reversing tubocurarine due to its ability to cross the blood-brain barrier and cause central effects.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the reversal of non-depolarizing neuromuscular blockers like tubocurarine can be achieved with acetylcholinesterase inhibitors like **neostigmine**. However, the use of neostigmine is often accompanied by **atropine** or **glycopyrrolate** to mitigate muscarinic side effects.

## **Correct Answer:** . Neostigmine